1-磷酸鞘氨醇受体调节剂治疗炎症性肠病的研究进展  

Research progress on the treatment of inflammatory bowel disease with sphingosine-1-phosphate receptor modulators

作　　者：曾雪 易宏伟 ZENG Xue;YI Hongwei(Dept.of Pharmacology,School of Medicine,Southeast University,Nanjing 210009,China)

机构地区：[1]东南大学医学院药理学系,南京210009

出　　处：《中国药房》2025年第7期881-886,共6页China Pharmacy

基　　金：国家自然科学基金项目(No.81872917,No.82373882)。

摘　　要：炎症性肠病(IBD)是一种胃肠道慢性炎症性疾病,目前其常规治疗药物存在特异性低、耐药性强等缺点。1-磷酸鞘氨醇受体(S1PR)调节剂是一种新型精准治疗药物,对IBD具有良好治疗效果。基于此,本文对S1PR调节剂的作用机制以及其在IBD治疗中的最新研究进展进行归纳,结果发现,S1PR调节剂可通过调节淋巴细胞迁移、降解受体、特异性调控S1PR,从而发挥抑制肠道炎症反应的作用。目前,Ozanimod与Etrasimod已获批用于治疗IBD,Amiselimod、KRP-203、Fingolimod、Ceralifimod虽未批准上市,但对IBD疾病展现出较大的潜力。Inflammatory bowel disease(IBD),a chronic gastrointestinal inflammatory disorder,is currently limited by conventional therapies due to its lack of specificity and pronounced drug resistance.Sphingosine-1-phosphate receptor(S1PR)modulators,as novel precision therapeutic agents,demonstrate promising efficacy in IBD treatment.This review synthesizes the mechanistic insights and recent advances in the treatment of IBD with S1PR.Our analysis reveals that S1PR modulators suppress intestinal inflammatory responses through three core mechanisms:regulating lymphocyte migration,inducing receptor degradation,and exerting subtype-specific S1PR modulation.Currently,Ozanimod and Etrasimod have been approved for IBD treatment,while Amiselimod,KRP-203,Fingolimod and Ceralifimod are not approved for clinical use,but have shown great potential for IBD disease.

关 键 词：炎症性肠病 1-磷酸鞘氨醇受体调节剂 1-磷酸鞘氨醇 Ozanimod Etrasimod 

分 类 号：R965[医药卫生—药理学]